Clinical Cardio Oncology

Clinical Cardio-oncology is a comprehensive, clinically focused title for cardiologists, oncologists, and specialists in cardio-oncology programs who need up-to-date knowledge about the cardiovascular effects of cancer treatment, especially on long-term cancer survivors. This brand-new resource covers the implementation of cardio-oncology into your practice, while a strong focus on patient management offers helpful information on coordinating care before, during, and after therapy. Its highly organized four-section format allows readers to quickly and easily locate relevant information. Comprised of four sections for quick and easy reference: Oncology and Hematology Principles; Cardiac Complications from Cancer Therapy; Coordination of Care; and Cardio-oncology in Practice. Provides expert wisdom from cardio-oncology authorities around the world, as well as consultation and perspectives from pioneers in the field of oncology. Highlights the principles of cancer therapies, including radiation and tumor therapy, as well as pre-, intra-, and post-therapy cardiology evaluation. Boasts chapters on implementing cardio-oncology into practice: primary cancer centers, comprehensive referral centers, group practices, and educational needs and goals for fellowship programs. Advises on how to coordinate care for the patient at every stage of treatment (pre-therapy, during therapy, after therapy, and end-of-life). Presents detailed information on various cardiac complications from cancer therapy, such as cardiomyopathy, vascular disease, arrhythmias, and hypertension. Teaches the principles of oncology and hematology with coverage of different therapy types and cardiac tumors. Includes a comprehensive drug guide.

Cardio-Oncology: Principles, Prevention and Management is a clinical volume that focuses on the basic science of cardio-oncology, addresses cardiotoxicity as a consequence of cancer therapy, and discusses prevention, diagnosis and management of cardiovascular disease in patients with cancer. This comprehensive volume presents unique perspectives ranging from basic science to clinical medicine in the field of cardio-oncology. It would be a valuable resource for cardiologists, oncologists, internists, and pediatricians caring for patients with cancer who have cardiovascular risk factors, as well as for cardio-oncology researchers. Covers basic science of cardio-oncology to provide readers with the necessary background Addresses cardiotoxicity related to current cancer therapeutic modalities Discusses diagnostic and management approaches of patients with underlying cardiac risk factors as well as otherwise healthy cancer patients

Today’s patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers. Covers all major cancer therapies, cardiovascular toxicities, and malignancies in a portable, authoritative guide—ideal for cardiologists, cardio-oncologists, general practitioners, internists, medical oncologists, and hematologists. Offers templated and streamlined content for quick retrieval, with key point summaries for each major section. Presents cardiac disease entities and specific malignant diseases in a succinct overview format addressing important clinical care aspects. Features "Central Illustrations" for each topic that visually summarize the chapter and its specific content including algorithms for management of cardiovascular toxicities and one-view overviews of malignancies. Includes a comprehensive drug guide that provides quick reference to drugs prescribed for cancers with therapeutic indications, manifestations and mechanisms of cardiotoxicity, their risk factors, and risk reduction strategies. Brings you up to date with new immune therapies, including immune checkpoint inhibitors and CAR T-cell therapies

This book takes a holistic view of the treatment of cardio-oncology patients, from evaluating those at high risk of developing cardio-toxicity, guidance for monitoring and managing patients during therapy to cardiac care of cancer survivors. Throughout, this book utilizes the latest research and guidance to offer advice on treatment strategy as well as practical elements of such as training, cardio-oncology nursing, patient education and how to establish a cardio-oncology unit. This book focuses on the practical knowledge and skills key to successful collaboration between cardiologists and oncologists to achieve the optimum cardiac care for cancer patients. Key Features Focuses on the practical elements of cardio-oncology care Outlines the importance and process of setting up a cardio-oncology unit and cardio-oncology fellowships Provides advice and guidance on the set up and common pit falls of coordinating care for cardio-oncology patients Outlines current guidelines and potential future directions for the field of cardio-oncology

This atlas provides a practically applicable didatic case-based guide to the use of cardiac imaging in patient care during and after cancer therapy. It features detailed information on a variety of imaging modalities, including transesophageal echocardiography, magnetic resonance angiography and positron emission tomography. A range of actual patient presentations are included covering both diagnosis and management during curative and palliative surgery, as well as cancer pharmacotherapy with the use of drugs including Trastuzumab, Anthracycline, Cisplatin and Carboplatin. Topics relevant to survivorship are also described. Atlas of Imaging in Cardio-Oncology enables the reader to develop a deep understanding of how to utilise a variety of imaging modalities used in cardio-oncology in a range of scenarios. It provides a critical and timely resource for the trainee and experienced cardiologist, oncologist and radiologist.

The book begins with the basic science behind the medical applications of the knowledge: cardiovascular biology, pathways, and their relationship to cancer treatment and principles of chemotherapy and immunotherapy. The second section consists of an overview and classification of anti-cancer drugs and a look at their cardiotoxicity. The third section looks at cardiac imaging in the cancer patient, including cardiac ultrasound, Doppler imaging, nuclear imaging, magnetic resonance imaging, and computed tomography in the cancer patient. In section four, management of cardiac disease in the cancer patient is discussed, including cardiac rhythm disturbances and heart failure. Cardiac emergencies and interventions are described as is preoperative assessment of the cancer patient for non- cardiovascular surgery. The final section includes a range of topics such as the pericardium, cardiovascular effects of endocrine treatments, primary cardiac tumors and malignancies of the myocardium and pericardium. Cardiac monitoring during clinical trials and pulmonary concerns are also addressed, as are psychosocial, social, economic, and legal issues of the cancer patient with heart disease.

"Clinical Cardio-oncology" is a comprehensive, clinically focused title for cardiologists, oncologists, and specialists in cardio-oncology programs who need up-to-date knowledge about the cardiovascular effects of cancer treatment, especially on long-term cancer survivors. This brand-new resource covers the implementation of cardio-oncology into your practice, while a strong focus on patient management offers helpful information on coordinating care before, during, and after therapy. Its highly organized four-section format allows readers to quickly and easily locate relevant information.

Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: • Cardiac complications in patients receiving cancer therapy • The treatment of cancer in patients with cardiovascular disease • The treatment of cardiovascular disease in patients with cancer When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.

Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death. Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications

This book comprehensively covers a range of pathological cases in clinical cardiology. Chapters are case focused and detail how a patient is diagnosed and treated in a step-by-step format. A range of engaging video clips enhances the reader’s appreciation and understanding of how to apply these techniques into their day-to-day clinical practice with special focus on congenital heart disease diagnosis and management. Case-Based Clinical Cardiology presents a range of clinical scenarios across all cardiology disciplines with a particular focus on echocardiography, electrocardiography and cardiac catheterization. Therefore, it is an ideal resource for both the novice and experienced cardiology practitioner seeking an up-to-date selection of cases to test their knowledge.

This book is designed for clinical cardiologists and other physicians working with cardiac patients, where specific specialized teams of cardio-oncologists are not available and who are called to perform a clinical consultation to evaluate both the cardiac condition and the eligibility for chemotherapy or radiotherapy treatment, and to evaluate if a cancer treatment produces toxic effects on a patient treated with chemo or radiotherapy and if appearance of new symptoms is due to this treatment. In recent years, progress in oncologic therapy has resulted in important developments and the prognostic improvement of patients with malignancy. The cornerstone of chemotherapy are the anthracyclines (and the analogue Mitoxantrone), that are direct cellular toxic agents and that are among the most powerful anti-neoplastic drugs, but their cardiac toxicity is well known. Significant breakthroughs in cancer therapy have also been achieved with the introduction of signalling inhibitors, such as VEGF inhibitors, HERB2 inhibitors or TK inhibitors used alone or in combination with direct cellular toxic drugs. However, these signalling inhibitors may interact also with cardiovascular signalling and therefore may have functional or structural effects on the myocardium. This can be permanent or reversible, with impairment of the global conditions and important side effects, and increase both morbidity and mortality and worsening of quality of life. Chemotherapy and radiotherapy can have acute detrimental effects that can be present for years after treatment and that can lead to cardiac consequences also after long periods of no clinic sequelae. Patient numbers with cancer problems will dramatically increase in the next years and thus every cardiologist will need to have the correct information and the skills to manage these situations in the correct way. This book will provide these tools for them.

The Department of Cardiology at The University of Texas MD Anderson Cancer Center was established on September, 1, 2000. In the past 15 years, we have evaluated and treated more than 10,000 cancer patients with cancer ther¬apy-related cardiovascular complications. Three years ago, we initiated the MD Anderson Practice (MAP) project to distillate our practice patterns into al¬gorithms to be shared with the onco-cardiology community. Because cancer is often an exclusion criterion for cardiology studies, purely evidence-based man¬agement of cancer therapy-related cardiovascular complications is not possible. With this vacuum of knowledge, various "guidelines" have proliferated that are either misleading or difficult to practice. In this manual, we present 16 MAPs that have been extensively reviewed by the cardiologists at MD Anderson. These MAPs should be considered our best practices rather than "guidelines." These MAPs will be updated frequently to reflect advances in the field. This manual con¬sists of MAPs, figures, and tables. We hope you will find these materials useful to your practice and provide us with feedback to improve these MAPs.

Screening for cancer is an important focus of cancer control. Yet screening, as it involves administering a test to large segments of the population deemed to be at risk for the disease of interest, is potentially a major consumer of scarce health care resources. In addition, the benefits sought from cancer screening, particularly reduction in mortality from the disease, are not always realized, either for biological or organizational reasons. Thus, the paradigm that `early detection must always be beneficial', taught to health care professionals, and publicized widely through the media to the public, has been challenged in the last two decades for a number of cancer sites. It is the purpose of Advances in Cancer Screening to determine the extent to which the requirements for the introduction of population-based screening programs have been met, as a result of extensive research on screening during the last two decades, with a major concentration on findings from the recent decade.

The authors of Women's Don't Ask present an innovative approach to negotiation that explains how women can identify important goals, takes them step by step through the entire planning and preparation process, and offers strategic advice on the negotiation stage, with tips on managing emotions, confidence building, and an effective collaborative style. Reprint. 20,000 first printing.

This issue of the Heart Failure Clinics of North America, guest edited by Drs. Daniel Lenihan and Douglas Sawyer, will cover several aspects of Cardio-oncology Related to Heart Failure. Subjects discussed in the volume include, but are not limited to: Proteasome Inhibitors as a potential cause of Heart Failure; EGFR target based therapy; Amyloidosis; How to manage Heart Failure in a patient with cancer; Advanced HF/Txp; Epidemiology and common risk factors; Pediatric Considerations; Alternative biomarkers for combined biology; How to develop a Cardio-Oncology Clinic; and How to structure a Cardio-Oncology fellowship program, among others.

Within the broad field of oncology is a relatively small but important area of cardiac oncology. The scope of cardiac oncology will increase as we con tinue to develop expertise in the detection and management of cardiac prob we intensify efforts to improve survival in patients who at an lems and as earlier time might have succumbed to advanced disease and a fragile cardio vascular system. With our aging population and the developing complexity of treatment modalities, we now recognize that the cardiovascular system is a target of the adverse effects of chemotherapy, radiotherapy, and cancer itself. The goal of this book is to present the scope of modern cardiac oncology as a growing discipline with sophisticated diagnostic testing and treatment modalities. The views of different specialists from different subspecialities are integrated to provide a multidisciplinary approach to the diagnosis, man agement, and complications of cancer of the heart and related conditions. The rapidly growing interest in cardiac oncology has largely been advanced through the ready availability of two-dimensional echocardiography, nuclear magnetic resonance imaging, angiocardiography, and other imaging tech niques. This book is divided into four parts. The first appraises cardiac tumors in detail and describes the distribution, pathology, noninvasive and invasive methods for testing, diagnosis, and treatment. The surgical approach to cardiac tumors has been included. It is a major advance that was essentially nonexistent a decade or so ago. Novel surgical approaches have now been successful in many instances.

This latest book in the Clinical Cases in Cardiology series presents a variety of commonly and rarely encountered cases associated with ​cardio-oncology. It explores the history of the discipline and each case described features concise practically orientated information on how to appropriately carry out physical examinations and utilize diagnostic tests including electrocardiography and monoclonal antibodies. Practically focused guidance is also provided on how to apply therapeutic techniques and the latest management strategies appropriately. Clinical Cases in Cardio-Oncology provides a concise practically applicable guide of how to diagnose and treat a range of conditions associated with ​cardio-oncology, making it a critical addition to the literature on the topic and a valuable resource for all medical practitioners who encounter these patients in their day-to-day practice.

Arterial hypertension, coronary heart disease and heart fail ure are the commonest cardiovascular conditions to present in clinical practice. Over the past few years it has become in creasingly clear that they are closely and causally interrelated and that their relationship can have a significant bearing on prognosis. Epidemiological studies have shown that arterial hypertension is one of the most important risk factors for de veloping heart failure. Only one in four patients with hyper tension is adequately managed, and in 50% of cases, the hypertension has not been recognised or treated. Patients with pre-existing hypertension who go on to suffer an acute myocardial infarction have usually not previously had typi cal angina symptoms, the infarct territory is larger, life threatening arrhythmias are commoner and hence in-hospi tal mortality and long-term prognosis are markedly worse. The presence of raised blood pressure in the post-infarct phase doubles the risk of manifest heart failure. The close relationship between hypertension, coronary heart disease and heart failure makes the choice of therapeu tic strategy particularly important. Agents and classes of agents that have prognostic value in all three conditions should be considered first, as synergy might result in addi tional benefits. In such patients, this sort of therapeutic deci sion-making might have further advantages. The use of these agents may prevent complications which are not yet clinically obvious (such as heart failure).

Cardiac tumors were once a nosographic entity of scarce clinical interest because of the rarity and of the intrinsic diagnostic and therapeutic impossibilities, and were considered a fatal morbid entity. It has now become a topical subject due to advances in clinical imaging (echo, magnetic resonance, computed tomography) as well as innovation in technologies of in-vivo diagnosis. Cardiac Tumor Pathology presents a spectacular example of these advances with clinico-pathologic correlations. This timely volume covers history, epidemiology, demographics, clinical diagnosis, pathology, imaging by echo, CT and MRI of both benign and malignant cardiac tumors, either primary or secondary. Chemotherapy of malignant neoplasms is also addressed. Special emphasis is given to clinico-pathologic correlations. With all chapters written by experts in their fields, this volume will serve as a useful resource for physicians dealing with, and interested in, this special branch of cardiac oncology and will represent a useful guide for pathologists, clinicians, cardiologists, cardiac surgeons, and radiologists as well as for postgraduate students training in these areas.